Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure

World J Gastroenterol. 2014 Mar 7;20(9):2403-11. doi: 10.3748/wjg.v20.i9.2403.

Abstract

Aim: To determine the prognostic value of circulating indicators of cell death in acute-on-chronic liver failure (ACLF) patients with chronic hepatitis B virus (HBV) infection as the single etiology.

Methods: Full length and caspase cleaved cytokeratin 18 (detected as M65 and M30 antigens) represent circulating indicators of necrosis and apoptosis. M65 and M30 were identified by enzyme-linked immunosorbent assay in 169 subjects including healthy controls (n = 33), patients with chronic hepatitis B (CHB, n = 55) and patients with ACLF (n = 81). According to the 3-mo survival period, ACLF patients were defined as having spontaneous recovery (n = 33) and non-spontaneous recovery which included deceased patients and those who required liver transplantation (n = 48).

Results: Both biomarker levels significantly increased gradually as liver disease progressed (for M65: P < 0.001 for all; for M30: control vs CHB, P = 0.072; others: P < 0.001 for all). In contrast, the M30/M65 ratio was significantly higher in controls compared with CHB patients (P = 0.010) or ACLF patients (P < 0.001). In addition, the area under receiver operating characteristic curve (AUC) analysis demonstrated that both biomarkers had diagnostic value (AUC ≥ 0.80) in identifying ACLF from CHB patients. Interestingly, it is worth noting that the M30/M65 ratio was significantly different between spontaneous and non-spontaneous recovery in ACLF patients (P = 0.032). The prognostic value of the M30/M65 ratio was compared with the Model for End-Stage Liver Disease (MELD) and Child-Pugh scores at the 3-mo survival period, the AUC of the M30/M65 ratio was 0.66 with a sensitivity of 52.9% and the highest specificity of 92.6% (MELD:AUC = 0.71; sensitivity, 79.4%; specificity, 63.0%; Child-Pugh: AUC = 0.77; sensitivity, 61.8%; specificity, 88.9%).

Conclusion: M65 and M30 are strongly associated with liver disease severity. The M30/M65 ratio may be a potential prognostic marker for spontaneous recovery in patients with HBV-related ACLF.

Keywords: Acute-on-chronic liver failure; Chronic hepatitis B virus infection; Liver disease severity; Liver disease stage; Prognostic value; Serum M30 level; Serum M65 level.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-On-Chronic Liver Failure / blood*
  • Acute-On-Chronic Liver Failure / diagnosis
  • Acute-On-Chronic Liver Failure / mortality
  • Acute-On-Chronic Liver Failure / therapy
  • Acute-On-Chronic Liver Failure / virology
  • Adult
  • Apoptosis
  • Area Under Curve
  • Biomarkers / blood
  • Case-Control Studies
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Hepatitis B, Chronic / blood*
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / mortality
  • Hepatitis B, Chronic / therapy
  • Humans
  • Keratin-18 / blood*
  • Liver / metabolism*
  • Liver / pathology
  • Liver / virology
  • Liver Transplantation
  • Male
  • Middle Aged
  • Necrosis
  • Peptide Fragments / blood*
  • Predictive Value of Tests
  • ROC Curve
  • Remission, Spontaneous
  • Time Factors
  • Up-Regulation

Substances

  • Biomarkers
  • Keratin-18
  • M30 cytokeratin-18 peptide, human
  • M65 antigen, human
  • Peptide Fragments